115 results
Page 2 of 6
6-K
EX-99.3
bv60qsigznnxx
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
uao uzyta3etyv3cm
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
npk1j4coe9eis32m
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
0m1yfmhsrs7091e
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
pb8q8gsnloo
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
ydorl88usfcblsk25s3
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
p6d4 h4bno5b
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
4jyn42q0jalgh agvv
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
3cgglxcskkus ekqw
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
nnciuywxjzbonz
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
b0rm8e4rba5r3s81ixa3
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
424B7
0yl8iqggae9cfjzf0ww
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.1
0kzb6wyhavyqm9z6
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.2
wcr7k7u8rvtqeh3vsrga
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
qf8 vqyybgd71bw8
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
9ki1ft 9ba
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.3
kwbzx4ly3jq klc
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am